Rubicon Research Limited reported a 44% year-on-year increase in revenue to ₹5,140 million for Q4FY26, driven by broad-based demand across its product portfolio. The company’s EBITDA grew 67% to ₹1,210 million, while profit after tax (PAT) surged 112% to ₹768 million. For the full fiscal year FY26, revenue stood at ₹17,540 million, a 37% increase, with PAT growing 84% to ₹2,467 million. The board has recommended a dividend of 150%, or ₹1.5 per share, translating to a 10% payout ratio.

Financial Performance

The strong growth trajectory was supported by a gross profit of ₹3,330 million for the quarter, up 39% YoY. R&D expenses increased to ₹594 million, representing 11.6% of operating revenues, reflecting the company’s focus on building its pipeline. On the balance sheet, shareholder funds reached ₹12,888 million, aided by IPO proceeds, while borrowings were reduced to ₹2,594 million. Net working capital days improved to 126 days from 137 days in the previous year.

Strategic Developments

The company received 12 product approvals from the US FDA in FY26, with 24 products currently under review, signaling a robust pipeline. The specialty portfolio contributed 33% of the gross profit for the quarter. Management highlighted that the Pithampur facility is on track for a ramp-up in Q1 of calendar year 2027, pending US FDA inspection. Additionally, the board approved a proposal to create an ESOP pool subject to shareholder approval.

Acquisition and Outlook

Rubicon Research completed the acquisition of an 85% stake in Arinna Lifesciences for an enterprise value of ₹200 crore on a cash and debt-free basis. This move strengthens the company’s CNS platform and provides a go-to-market infrastructure in India. Despite increased reliance on outsourced manufacturing due to higher-than-anticipated demand, the company maintained its EBITDA margin guidance range of 22% to 23% for the coming quarters.

Rubicon Research Limited reported a strong financial performance for the quarter and year ended March 31, 2026 (FY26), with net profit for the quarter rising 112% to ₹768 million from ₹362 million in the corresponding period of the previous year. Revenue from operations for Q4FY26 increased 44% to ₹5.14 billion compared to ₹3.58 billion in Q4FY25, driven by robust growth across its pharmaceutical product portfolio. For the full year FY26, net profit rose 84% to ₹2.47 billion and revenue increased 37% to ₹17.54 billion. The Board has recommended a final dividend of ₹1.50 per equity share, subject to shareholder approval.

Key Financial Highlights

The company's audited consolidated financial results for FY26 demonstrated significant improvement across major metrics. Earnings per share (EPS) for the year increased to ₹15.52 from ₹8.82 in the prior year. The statutory auditors, M/s. Deloitte Haskins & Sells LLP, issued an audit report with an unmodified opinion on the financial results.

Operational and Strategic Developments

Revenue growth was broad-based, with the top 5 products contributing 39% of revenue in Q4FY26 compared to 34% in Q1FY26. USD revenue for Q4FY26 stood at $56 million, up 35% year-on-year, with approximately 98% of total revenue being USD denominated. Specialty products contributed 32.8% to gross profit for the quarter. The company received 12 product approvals in FY26, and 24 products were under review by the USFDA as of March 31, 2026.

Management noted that while gross margins contracted slightly sequentially to 66.3% due to reliance on outsourced manufacturing, Operating EBITDA margin sustained in the 22-23% range. The Pithampur site has been qualified and filed with the USFDA, with production ramp-up expected in Q1 CY27. The company also completed an Initial Public Offering (IPO) during the year, aggregating to ₹13.78 billion, with shares listed on the NSE and BSE on October 16, 2025.